Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

FDA Grants Ampio Pharma Approval to Begin Phase 1 Trial in COVID-19 Patients

Ampio Pharmaceuticals' shares traded higher after the company reported that the FDA cleared the firm to proceed with human trials of its Investigative New Drug application for intravenous AmpionTM for treatment in COVID-19 affected patients on supplemental oxygen. ...
Streetwise Reports | June 22, 2020 |

BioNTech, CureVac, Valeo Pharma - COVID-19 wakes up the industry

In the past, people have accepted that it usually takes about ten years to get a vaccine on the market. Careful testing with proof of success is required for a preparation to receive approvals. Since COVID-19, the pressure to develop has increased dramatically and also the pot...
Mario Hose | September 1, 2020 |

Analyst: Biopharma, Now Stronger Than Ever, Is an Ideal Takeout Target

An argument is made in a ROTH Capital Partners report for a potential imminent deal involving this drug maker. In an April 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi reviewed the reasons why Galmed Pharmaceuticals Ltd. (GLMD:NASDAQ) is "high on the...
Streetwise Reports | April 18, 2019 |

Health Technology Company Recuperating Well

Technical analyst Clive Maund charts a medical technology firm and explains why he believes it is an interesting speculative play. Today, by way of a change from resource stocks, we are going to look at an interesting medical stock, which looks like it i...
Streetwise Reports | July 6, 2019 |

Biopharma to Accelerate Alzheimer Trial Completion

The upcoming catalysts for Axsome Therapeutics and the effects of COVID-19 on its clinical activities are discussed in an H.C. Wainwright & Co. report. In a March 20 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that Axsome Therapeutics Inc. ...
Streetwise Reports | March 26, 2020 |

Precious Metals Miner Reevaluates Nevada Operations After Q1/19 Miss

The reasons for the miss and possible paths forward were outlined in a ROTH Capital Partners report. In a May 9 research note, analyst Jake Sekelsky reported that ROTH Capital Partners reduced its target price on Hecla Mining Co. (HL:NYSE) to $3 per share ...
Streetwise Reports | May 21, 2019 |

Vir Partners with Samsung Biologics on Large-Scale Manufacture of COVID-19 Antibody Treatment

Vir Biotechnology reported it has entered into an agreement with Samsung Biologics valued at $362 million for large-scale manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment. Though U.S. markets are closed for the Good Friday holiday, Samsung Biologics shar...
Streetwise Reports | April 13, 2020 |

Apache and Total Form $5 Billion Joint Venture to Drill off Suriname Coast

Shares of Apache Corp. traded 16% higher today after the company reported that it has formed a joint venture with Total SA of France to explore and develop Block 58 offshore Suriname. Late yesterday evening, oil and gas exploration and production company Apache Corp....
Streetwise Reports | December 27, 2019 |

Surface Oncology Shares Trade Up 40% on Phase1 Study Plans for SRF617 Combined with Merck's KEYTRUDA

Shares of Surface Oncology set a new 52-week high price after the company reported that it is partnering with Merck & Co. in an immuno-oncology study of SRF617, targeting CD39 in combination with KEYTRUDA® (pembrolizumab) in solid tumor patients. Clinical-...
Streetwise Reports | May 21, 2020 |

Large US Market Now Open to Livestock Feed Antibiotic Replacement

Proprietary OxC-beta livestock feed supplement can supplant the need for maintenance antibiotics. Antibiotic resistance is a major health threat worldwide and many countries have banned or are banning the use of antibiotics as growth promoters in livestock. The European...
Streetwise Reports | March 12, 2019 |
1 2 3 4 5 6 7 8 9 10 ...